Innate Pharma S.A.
IPHYF · OTC
6/30/2025 | 12/31/2024 | 6/30/2024 | 12/31/2023 | |
|---|---|---|---|---|
| Market Cap | $141,262 | $226,989 | $143,662 | $207,057 |
| - Cash | $53,704 | $66,396 | $69,990 | $70,605 |
| + Debt | $27,029 | $30,995 | $35,503 | $39,893 |
| Enterprise Value | $114,587 | $191,588 | $109,175 | $176,345 |
| Revenue | $4,860 | $276 | $12,345 | $21,443 |
| % Growth | 1,660.9% | -97.8% | -42.4% | – |
| Gross Profit | -$15,660 | $29,352 | -$16,731 | -$3,126 |
| % Margin | -322.2% | 10,634.8% | -135.5% | -14.6% |
| EBITDA | -$25,061 | -$21,348 | -$25,563 | -$10,396 |
| % Margin | -515.7% | -7,734.8% | -207.1% | -48.5% |
| Net Income | -$21,344 | -$24,707 | -$24,764 | -$9,288 |
| % Margin | -439.2% | -8,951.8% | -200.6% | -43.3% |
| EPS Diluted | -0.25 | -0.3 | -0.31 | -0.12 |
| % Growth | 16.7% | 3.2% | -158.3% | – |
| Operating Cash Flow | -$31,164 | -$9,932 | $3,036 | -$21,093 |
| Capital Expenditures | -$58 | -$108 | -$283 | -$42 |
| Free Cash Flow | -$31,222 | -$10,040 | $2,753 | -$21,135 |